Intellia Therapeutics, Inc.
NTLA
$8.50
$0.4255.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -42.54% | 771.57% | -24.02% | -48.82% | 129.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.54% | 771.57% | -24.02% | -48.82% | 129.53% |
| Cost of Revenue | -3.06% | 7.25% | 8.52% | -0.93% | 15.17% |
| Gross Profit | -10.72% | 6.22% | -12.35% | -5.48% | 1.89% |
| SG&A Expenses | -6.70% | 11.90% | 3.73% | 3.72% | 13.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.85% | 8.22% | 7.53% | 0.05% | 14.75% |
| Operating Income | -5.97% | 2.46% | -10.42% | -5.07% | -1.83% |
| Income Before Tax | -6.42% | 2.47% | -11.04% | -18.83% | -4.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.42% | 2.47% | -11.04% | -18.83% | -4.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.42% | 2.47% | -11.04% | -18.83% | -4.18% |
| EBIT | -5.97% | 2.46% | -10.42% | -5.07% | -1.83% |
| EBITDA | -6.12% | 2.58% | -10.36% | -4.82% | -1.44% |
| EPS Basic | 1.81% | 13.38% | 2.55% | -8.06% | 4.25% |
| Normalized Basic EPS | -2.14% | 15.45% | 4.76% | 6.90% | 9.57% |
| EPS Diluted | 1.81% | 13.38% | 2.55% | -8.06% | 4.25% |
| Normalized Diluted EPS | -2.14% | 15.45% | 4.76% | 6.90% | 9.57% |
| Average Basic Shares Outstanding | 8.37% | 12.60% | 13.94% | 9.97% | 8.81% |
| Average Diluted Shares Outstanding | 8.37% | 12.60% | 13.94% | 9.97% | 8.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |